GO:0044325 transmembrane transporter binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0044325 (transmembrane transporter binding) is a molecular function describing the binding of a protein to a transmembrane transporter, a protein or complex that moves substances across a membrane.
• The term is synonymous with ion channel binding and is distinct from transporter activity itself; it captures regulatory, scaffolding, and assembly interactions.
• Transmembrane transporter binding is central to diverse physiological processes, including nutrient uptake, ion homeostasis, hormone transport, and drug disposition [2,5].
• Dysregulation of these interactions contributes to diseases such as cancer, neurological disorders, and metabolic syndromes [2,5].
• Key experimental approaches include knockout, point-mutation, knock-in, and overexpression models, combined with biochemical binding assays and structural biology [3,4,7].
• EDITGENE provides comprehensive CRISPR services to dissect transmembrane transporter binding mechanisms and validate therapeutic targets [3,4,8].
Description
Transmembrane transporter binding (GO:0044325) is a molecular function that defines the physical interaction between a protein and a transmembrane transporter, which is a protein or protein complex that facilitates the movement of substances across a membrane. This binding event is fundamental to the regulation, assembly, and functional modulation of transporters, impacting a wide array of biological processes from nutrient uptake to signal transduction [2,5]. Understanding these interactions is crucial for researchers aiming to decipher cellular physiology and develop targeted therapeutics [2,5]. The term is often used interchangeably with ion channel binding, reflecting its broad relevance to membrane transport systems. In this article, we explore the definition, mechanisms, key genes, and research methodologies associated with GO:0044325, providing a comprehensive resource for biomedical scientists [3,4,7].
transmembrane transporter binding At A Glance
| GO ID | GO:0044325 |
|---|---|
| GO term | transmembrane transporter binding |
| Ontology | molecular_function |
| Synonym | ion channel binding |
| Major function | Binding to transmembrane transporters to modulate their activity, assembly, or localization |
| Related processes | Transport, signal transduction, homeostasis |
| Examples | Binding to ABC transporters, urea transporters, P-type ATPases |
What Is GO:0044325?
GO:0044325, transmembrane transporter binding, is defined as the binding to a transmembrane transporter, a protein or protein complex that enables the transfer of a substance, usually a specific substance or a group of related substances, from one side of a membrane to the other. This molecular function encompasses interactions that may regulate transporter activity, localization, or stability, and is synonymous with ion channel binding.
Why Is transmembrane transporter binding Important in Cell Biology?
Transmembrane transporter binding is essential for understanding how cells regulate the movement of ions, nutrients, and drugs across membranes [2,5]. This function impacts drug pharmacokinetics, hormone signaling, and cellular stress responses, making it a critical area of study for pharmacology, physiology, and disease research [2,5].
• Regulates transporter activity and substrate specificity, influencing cellular uptake and efflux.
• Modulates drug transport and pharmacokinetics, affecting therapeutic efficacy and toxicity.
• Controls ion homeostasis and membrane potential, critical for neuronal and cardiac function.
• Participates in hormone transport, such as thyroid hormones, impacting metabolism.
• Involved in lipid-mediated regulation of transporter function.
• Dysregulation linked to cancer, neurological disorders, and metabolic diseases [2,5].
• Provides targets for pharmacological intervention in transport-related pathologies.
• Essential for understanding membrane protein assembly and quality control.
• Facilitates structural studies of transporter complexes [3,7].
• Enables CRISPR-based functional genomics of transport systems [3,4,8].
What Happens During transmembrane transporter binding?
Recognition and Initial Contact
In simple terms: The binding protein finds and attaches to a specific transporter on the membrane.
The process begins with the recognition of a transmembrane transporter by a binding partner, often through electrostatic or hydrophobic interactions. This initial contact can be influenced by membrane lipid composition, which affects transporter conformation and accessibility. For example, lipoprotein recognition by LolCDE involves specific binding events that are essential for transport.
Conformational Changes and Complex Formation
In simple terms: Binding causes shape changes in the transporter, leading to a stable complex.
Upon binding, conformational changes in the transporter can occur, leading to the formation of a stable complex that may modulate transport activity [3,7]. Structural studies of urea transporters have revealed distinct inhibition modes upon binding of regulatory proteins. Similarly, P-type ATPases like ERMA undergo conformational transitions during Mg2+ uptake, which are regulated by binding partners.
Functional Modulation of Transport
In simple terms: The binding event can turn the transporter on or off, or change what it transports.
Binding can enhance or inhibit transporter activity, alter substrate specificity, or affect trafficking to the membrane [2,5]. For instance, thyroid hormone transport is modulated by binding proteins that influence transporter function. In drug transport, binding interactions can lead to natural product-drug interactions.
Downstream Signaling and Cellular Responses
In simple terms: The binding triggers signals inside the cell that change its behavior.
Transmembrane transporter binding can initiate signaling cascades that affect gene expression, metabolism, or cell survival [1,5]. This is particularly relevant in cancer, where transporter-binding proteins can promote drug resistance or tumor growth.
Key Genes Involved in GO:0044325 transmembrane transporter binding
The following genes encode proteins that are known to bind transmembrane transporters or are themselves transporters involved in binding interactions, based on published literature [1-8].
| Gene | Major Role | Research Relevance |
|---|---|---|
| ABCB1 | ATP-binding cassette transporter; binds various substrates and regulatory proteins | Drug resistance, pharmacokinetics [1,2] |
| SLC14A1 | Urea transporter; binding regulates urea permeation | Kidney function, urea cycle disorders |
| ATP2C1 | P-type ATPase; binds Mg2+ and regulatory proteins | Magnesium homeostasis, ER function |
| LolCDE | Lipoprotein transporter complex; binds lipoproteins | Bacterial lipoprotein transport |
| THRA | Thyroid hormone receptor; binds thyroid hormones and transporters | Thyroid hormone transport |
| CFTR | Chloride channel; binds regulatory proteins | Cystic fibrosis, ion transport |
| KCNQ1 | Potassium channel; binds auxiliary subunits | Cardiac arrhythmia |
| SCN5A | Sodium channel; binds regulatory proteins | Brugada syndrome |
| ATP1A1 | Na+/K+-ATPase; binds regulatory proteins | Ion homeostasis |
| SLC2A1 | Glucose transporter; binds regulatory proteins | GLUT1 deficiency |
| SLC22A1 | Organic cation transporter; binds drugs | Drug disposition |
| ABCC2 | Multidrug resistance protein; binds substrates | Biliary transport |
| SLC7A11 | Cystine/glutamate transporter; binds regulatory proteins | Cancer metabolism |
| TMEM94 | ER Mg2+ transporter; binds Mg2+ | ER homeostasis |
| SLC5A5 | Sodium-iodide symporter; binds ions | Thyroid function |
| ABCB11 | Bile salt export pump; binds bile salts | Cholestasis |
| SLC6A4 | Serotonin transporter; binds antidepressants | Depression, drug response |
How Is transmembrane transporter binding Regulated?
Transmembrane transporter binding is regulated by various factors, including membrane lipid composition, post-translational modifications, and interacting proteins. For example, membrane lipids can directly modulate transporter function by altering binding affinities. Additionally, hormonal signals such as thyroid hormones can regulate the expression and activity of transporters and their binding partners. In bacteria, lipoprotein transport is tightly regulated by the LolCDE complex.
transmembrane transporter binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ABCB1 | Multidrug resistance in cancer | Knockout in cancer cell lines, drug sensitivity assays |
| SLC14A1 | Urea cycle disorders, kidney dysfunction | Point mutation knock-in in HEK293 cells, urea transport assays |
| ATP2C1 | Hailey-Hailey disease, Mg2+ imbalance | Knockout in keratinocytes, Ca2+ imaging |
| KCNQ1 | Long QT syndrome, arrhythmia | Knock-in of patient mutations in iPSC-derived cardiomyocytes |
| LolCDE | Bacterial infections | Knockout in E. coli, lipoprotein transport assays |
Cancer and Drug Resistance
Altered transmembrane transporter binding can lead to multidrug resistance in cancer cells, as transporters like ABCB1 efflux chemotherapeutic agents. Binding proteins may enhance or inhibit this efflux, influencing treatment outcomes.
Neurological Disorders
Ion channel binding is critical for neuronal excitability; mutations in binding interfaces can cause epilepsy or arrhythmias. For instance, KCNQ1 binding partners affect cardiac action potentials.
Metabolic and Endocrine Diseases
Thyroid hormone transport relies on specific transporter-binding interactions; disruptions can lead to hypothyroidism or resistance. Similarly, urea transporter binding defects cause kidney disorders.
Infectious Diseases
Bacterial lipoprotein transport via LolCDE is essential for viability; binding inhibitors are potential antibiotics.
From transmembrane transporter binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X bind to transporter Y? | Knockout of gene X, co-immunoprecipitation |
| What is the affinity of binding? | Point mutations in binding interface, surface plasmon resonance |
| Does binding regulate transport activity? | Overexpression of binding protein, transport assays |
| Where does binding occur in the cell? | Tagged knock-in, fluorescence microscopy |
| What are the downstream effects of binding? | Knockout + RNA-seq, proteomics |
| Can binding be targeted therapeutically? | Overexpression of dominant-negative mutant, drug screening |
How to Study the transmembrane transporter binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Co-immunoprecipitation | Protein-protein interactions | Identifying binding partners |
| Surface plasmon resonance | Binding affinity and kinetics | Quantifying interactions |
| Cryo-EM | 3D structure of complexes | Visualizing binding interfaces |
| Transport assays | Substrate flux | Functional impact of binding |
| CRISPR knockout | Loss-of-function effects | Validating gene function |
| RNA-seq | Transcriptional changes | Downstream signaling |
| Proteomics | Protein abundance and modifications | Global binding networks |
Biochemical Binding Assays
Co-immunoprecipitation, pull-down, and surface plasmon resonance are used to detect and quantify binding between proteins and transporters [1,4].
Structural Biology
Cryo-EM and X-ray crystallography reveal atomic details of transporter-binding complexes, as shown for urea transporters and LolCDE [4,7].
Functional Transport Assays
Radiolabeled substrate uptake or efflux assays measure how binding affects transport activity [2,5].
Genetic and Genomic Approaches
CRISPR knockout, knock-in, and overexpression models combined with RNA-seq or proteomics identify binding partners and downstream effects [3,8].
How CRISPR Can Be Used to Study GO:0044325 transmembrane transporter binding
Knockout
CRISPR knockout of genes encoding transporters or their binding partners can reveal loss-of-function phenotypes, such as altered transport activity or drug sensitivity [3,8].
Point Mutation
Introducing point mutations in binding interfaces via CRISPR can dissect specific residues critical for interaction, as demonstrated for P-type ATPases.
Knock-in
Knock-in of tagged or mutant versions of transporters allows tracking of localization and binding dynamics in live cells.
Overexpression
Overexpression of binding proteins or transporters can amplify binding effects, useful for biochemical and structural studies [2,7].
How EDITGENE Supports transmembrane transporter binding Research
Researchers studying transmembrane transporter binding-related genes often need to determine whether a candidate gene is causally involved in transport regulation, disease progression, or drug response. EDITGENE provides end-to-end CRISPR solutions to generate precisely engineered cell models, enabling functional validation and mechanistic insights.
Contact EDITGENE today to design your custom CRISPR model for transmembrane transporter binding research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SCN10A Overexpression HEK293T Stable Cell Line | EDC01586 | Human | 6336 | Details Get a Quote |
| CTNNB1 Knockout HCT 116 Cell Line | EDJ-KQ22 | Human | 1499 | Details Get a Quote |
| TRAPPC2 Knockout HeLa Cell Line | EDJ-KQ27 | Human | 6399 | Details Get a Quote |
| ACTN1 Knockout HEK293T Cell Line | EDJ-KQ99 | Human | 87 | Details Get a Quote |
| CAMK2D Knockout HEK293 Cell Line | EDJ-KQ111 | Human | 817 | Details Get a Quote |
| FLNA Knockout HEK293 Cell Line | EDJ-KQ171 | Human | 2316 | Details Get a Quote |
| HSP90AA1 Knockout HEK293 Cell Line | EDJ-KQ200 | Human | 3320 | Details Get a Quote |
| FMR1 Knockout HEK293T Cell Line | EDJ-KQ215 | Human | 2332 | Details Get a Quote |
| CTNNB1 Knockout HEK293 Cell Line | EDC07547 | Human | 1499 | Details Get a Quote |
| ID2 Knockout HEK293 Cell Line | EDJ-KQ383 | Human | 3398 | Details Get a Quote |
| FHL1 Knockout HEK293 Cell Line | EDJ-KQ462 | Human | 2273 | Details Get a Quote |
| LYN Knockout HEK293 Cell Line | EDJ-KQ574 | Human | 4067 | Details Get a Quote |
| NOS1 Knockout HEK293 Cell Line | EDJ-KQ844 | Human | 4842 | Details Get a Quote |
| SLC8A1 Knockout HEK293 Cell Line | EDJ-KQ849 | Human | 6546 | Details Get a Quote |
| YWHAE Knockout HEK293 Cell Line | EDJ-KQ880 | Human | 7531 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »
Frequently Asked Questions About transmembrane transporter binding
What is transmembrane transporter binding?
It is a molecular function (GO:0044325) where a protein binds to a transmembrane transporter, regulating its activity or assembly.
What genes are involved in transmembrane transporter binding?
Genes include ABCB1, SLC14A1, ATP2C1, and many others encoding transporters or their binding partners [1-8].
How is transmembrane transporter binding studied?
Common methods include co-immunoprecipitation, structural biology, transport assays, and CRISPR screens [3,4,7].
Why is transmembrane transporter binding important in cancer?
It affects drug efflux and resistance; binding proteins can modulate ABC transporter activity.
What diseases are linked to transmembrane transporter binding?
Cancer, neurological disorders, metabolic diseases, and infections [2,5,7].
Can CRISPR be used to study transmembrane transporter binding?
Yes, knockout, knock-in, and point mutation models help dissect binding mechanisms [3,8].
What is the synonym for GO:0044325?
Ion channel binding.
Which databases provide information on GO:0044325?
QuickGO and PubMed literature [1-8].
How does membrane lipid composition affect transporter binding?
Lipids can alter transporter conformation and binding affinity.
What are potential therapeutic targets in this pathway?
Transporters and their binding interfaces, especially in cancer and infections [2,4].
Conclusion
Transmembrane transporter binding (GO:0044325) is a fundamental molecular function that governs the regulation of membrane transport systems. Its implications span physiology, pharmacology, and disease, making it a vibrant area of research. Leveraging CRISPR-based models and biochemical assays, scientists can unravel the complexities of these interactions and identify new therapeutic targets. EDITGENE offers comprehensive services to support these endeavors, from knockout to overexpression and screening.
References
- 1. Rea PA. 2007. Plant ATP-binding cassette transporters.. Annu Rev Plant Biol 58:347-75 PMID: 17263663
- 2. Bi Y et al.. 2023. Transporter-mediated Natural Product-Drug Interactions.. Planta Med 89(2):119-133 PMID: 35304735
- 3. Santarossa CC et al.. 2026. LetA defines a structurally distinct transporter family.. Nature 651(8107):1097-1106 PMID: 41565823
- 4. Qiao W et al.. 2024. Deciphering the molecular basis of lipoprotein recognition and transport by LolCDE.. Signal Transduct Target Ther 9(1):354 PMID: 39725716
- 5. Braun D et al.. 2018. Thyroid Hormone Transport and Transporters.. Vitam Horm 106:19-44 PMID: 29407435
- 6. Stieger B et al.. 2021. Membrane lipids and transporter function.. Biochim Biophys Acta Mol Basis Dis 1867(5):166079 PMID: 33476785
- 7. Huang SM et al.. 2024. Structural insights into the mechanisms of urea permeation and distinct inhibition modes of urea transporters.. Nat Commun 15(1):10226 PMID: 39587082
- 8. Vishnu N et al.. 2024. ERMA (TMEM94) is a P-type ATPase transporter for Mg(2+) uptake in the endoplasmic reticulum.. Mol Cell 84(7):1321-1337.e11 PMID: 38513662
